There are 412 resources available
178P - Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients
Presenter: Leonardo Provenzano
Session: Poster session 01
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
2300P - Clonal hematopoiesis of indeterminate potential (CHIP) in patients with advanced NSCLC treated with immune checkpoint blockers (ICB) as monotherapy: Analysis of the PREMIS study
Presenter: Julieta Rodriguez
Session: Poster session 08
LBA99 - First survival data from the NIPU trial: A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second-line treatment in patients with malignant mesothelioma
Presenter: Aaslaug Helland
Session: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1482P - Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in elderly adults aged over 75 years
Presenter: Jun Sakakibara-Konishi
Session: Poster session 21
1372P - Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
Presenter: Ben Solomon
Session: Poster session 20
CN90 - Managing the increasing capacity pressures in a nurse-led rural, satellite oncology unit in the era of immunotherapy
Presenter: SANDRA MURPHY
Session: Poster session 25
Resources:
Abstract
235TiP - Hamlet.rt Trans: Prospective single-centre translational study evaluating liquid biomarkers of radiation response
Presenter: Mary Denholm
Session: Poster session 02